Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments: 2020-2025

Historic Short-term Investments for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $1.4 million.

  • Apellis Pharmaceuticals' Short-term Investments rose 4.15% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 4.15%. This contributed to the annual value of $1.3 million for FY2024, which is 18.67% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Short-term Investments stood at $1.4 million for Q3 2025, which was down 0.00% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Short-term Investments ranged from a high of $458.2 million in Q1 2021 and a low of $1.1 million during Q2 2023.
  • In the last 3 years, Apellis Pharmaceuticals' Short-term Investments had a median value of $1.3 million in 2024 and averaged $1.3 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first spiked by 100.27% in 2021, then plummeted by 99.62% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Short-term Investments (Quarterly) stood at $60.4 million in 2021, then slumped by 97.89% to $1.3 million in 2022, then decreased by 12.49% to $1.1 million in 2023, then increased by 18.67% to $1.3 million in 2024, then increased by 4.15% to $1.4 million in 2025.
  • Its Short-term Investments was $1.4 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.4 million in Q1 2025.